

eISBN: 978-1-68108-371-1
ISBN: 978-1-68108-372-8

PAIN CAUSES, CONCERNS AND CONSEQUENCES

Editors:
Puneetpal Singh
Monica Singh

Bentham  Books

Pain: Causes, Concerns and Consequences

Edited By:

Puneetpal Singh

&

Monica Singh

Human Genetics Punjabi University

Patiala

India

Pain: Causes, Concerns and Consequences

Editor: Puneetpal Singh

ISBN (eBook): 978-1-68108-371-1

ISBN (Print): 978-1-68108-372-8

© 2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE.
All Rights Reserved.

First published in 2016.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	kv
DEDICATION	v
CHAPTER 1 PAIN: A CLINICIAN'S JOURNEY	3
<i>F cxf "UDc iugt</i>	
INTRODUCTION	3
PART 1	4
Pain: a Clinician's journey	4
Pain; A Theoretical and Applied, Integrative Clinical and Research Understanding	5
CONCLUSION	11
PART 2	12
The Clinician Detective: Applying the Clinician's Journey to Patient Management.	12
CONFLICT OF INTEREST	14
ACKNOWLEDGEMENT	14
REFERENCES	14
CHAPTER 2 FUNCTIONAL BRAIN CIRCUITRY IN CENTRAL POST-STROKE PAIN	17
<i>Cpft gy "Ej kj "Y gkJ wcp i . "J ukcp i /Ej kp "Nw'cpf "DckEj wcp i "Uj {w</i>	
INTRODUCTION	17
1. CLINICAL SYMPTOMS OF CENTRAL POST-STROKE PAIN	18
2. PATHOGENESIS-RELATED HYPOTHESES OF CENTRAL POST-STROKE PAIN	20
2.1. Central Disinhibition	20
2.2. Central Imbalance	20
2.3. Central Sensitization	21
3. FUNCTIONAL BRAIN ACTIVITY MAPPING	22
3.1. Human Neuroimaging of Central Post-stroke Pain	22
3.2. Animal Neuroimaging of CPSP	27
3.3. [14C] Iodoantipyrine Data and Region-of-Interest Analysis of CPSP in Animal Models	27
4. NEURAL CORRELATIONS AND FUNCTIONAL NETWORKS IN THE BRAIN	33
CONCLUSION	35
CONFLICT OF INTEREST	36
ACKNOWLEDGEMENTS	36
REFERENCES	36
CHAPTER 3 THE ROLE OF PSYCHOLOGICAL FACTORS IN CARDIAC AND NON-CARDIAC CHEST PAIN	40
<i>O cuqwo crk'O cuqwo k "O q/ j i cp "U: glf k'cpf "U: glf "Mqo cuk</i>	
INTRODUCTION	40
CARDIAC CHEST PAIN (CCP)	41
Epidemiology	42
Etiology	42
<i>Cardiac Chest Pain and Mechanism of Pain</i>	42
<i>Myocardial Ischemia Syndrome</i>	43
<i>Dissecan Aortic Aneurysm and Mechanisms of Pain</i>	46
Endothelial Dysfunction and the Impact of Psychological Factors	46
Psychological Etiology	48
CCP Outcomes and Psychological Distress	49
CCP and Psychotherapy	50

<i>The Indications for Psychotherapy and Hypnotherapy</i>	52
NON-CARDIAC CHEST PAIN (NCCP)	53
Epidemiology	53
Etiology	53
Psychological Etiology	54
Differential Diagnosis	55
<i>Differentiated Impact of Pain with Organic or Psychological Origin</i>	56
NCCP Outcomes and Psychological Distress	56
NCCP and Psychotherapy	58
CONFLICT OF INTEREST	60
ACKNOWLEDGEMENTS	60
REFERENCES	60
CHAPTER 4 GENETIC EXPLORATIONS OF PAIN	73
<i>J ct lqvFj kmp'cpf 'Rwpggv cn'Upi j</i>	
INTRODUCTION	73
1. TRANSDUCTION	74
Heat Pain	74
Mechanical Pain	76
Cold Pain	76
Chemical Stimuli	77
2. CONDUCTION	80
3. TRANSMISSION	86
4. MODULATION	90
CONCLUSION	95
CONFLICT OF INTEREST	96
ACKNOWLEDGEMENTS	96
REFERENCES	96
CHAPTER 5 NON-PHARMACOLOGICAL TREATMENT OPTIONS FOR COEXISTING CHRONIC NON-CANCER PAIN AND SUBSTANCE USE DISORDER	111
<i>Rgygt 'Rt/gmqr</i>	
INTRODUCTION	112
The Scope of the CNCP Problem	112
The Patient with CNCP and SUD	113
An Approach to the Patient with CNCP and SUD	114
<i>History of Present Illness (HPI)</i>	114
Other Factors	114
<i>Physical Exam</i>	115
Potential Treatments	115
Movement	115
Energy Therapies	116
Psychosocial Treatments	117
Other Treatments	118
<i>Treating the patient using alternative techniques</i>	119
<i>Final considerations</i>	121
CONFLICT OF INTEREST	121
ACKNOWLEDGEMENTS	122
REFERENCES	122
CHAPTER 6 MICRORNAS: THE TINY ROBUST PLAYERS UNRAVELING THE MULTIFACETED CHANNELS OF PAIN	126
<i>[qi kc 'MOCf wnj c</i>	
INTRODUCTION	127

Pain	127
MicroRNA	128
<i>Biogenesis of MiRNA and their Mechanism of Action</i>	129
Expression Profile of MiRNAs in Different Animal Models of Pain	133
<i>Regulation of MicroRNAs in Peripheral Somatic Sensory Neurons</i>	137
Translational aspect of MiRNA Biology in Pain Therapeutics	143
<i>Prediction and Experimental Validation of MiRNA Targets</i>	144
Roadblocks in Translating MiRNA Biology to Pain Therapeutics	147
CONCLUDING REMARKS AND FUTURE PERSPECTIVES	148
CONFLICT OF INTEREST	149
ACKNOWLEDGEMENTS	150
ABBREVIATIONS	150
REFERENCES	150

CHAPTER 7 THE AMELIORATIVE POTENTIAL OF 7-HYDROXY-4-METHYLCOUMARIN IN ACRYLAMIDE INDUCED NEUROPATHIC PAIN *via* IMPROVING OF MITOCHONDRIAL FUNCTION IN RAT

<i>Lcirt ggy/Mcwt. 'Ctwpcej crco 'Owj wtco cp'cpf 'Owj wcco {'Tco guj</i>	161
INTRODUCTION	162
MATERIALS AND METHODS	164
Drugs and Chemicals	164
Animals	164
Induction of Neuropathic Pain	164
Assessment of Behavioral Pain Sensation	165
<i>Acetone Drop Test</i>	165
<i>Plantar Test</i>	165
<i>Hot Plate Test</i>	165
<i>Von Frey Hair Test</i>	166
<i>Tail Immersion Test</i>	166
Estimation of Tissue Biomarkers Changes	166
<i>Estimation of Total Protein Content</i>	167
<i>Estimation of Thiobarbituric Acid Reactive Substances (TBARS)</i>	167
<i>Estimation of Reduced Glutathione (GSH) Content</i>	168
<i>Estimation of Total Calcium</i>	168
Assessment of Mitochondrial Function	168
<i>Preparation of Mitochondria</i>	168
<i>Estimation of Cytochrome C Oxidase Activity and ATP Content</i>	169
Experimental Protocol	169
Statistical Analysis	170
RESULTS	170
Effect of HMC on Acetone Drop Test	170
Effect of HMC on Plantar Test	171
Effect of HMC on Hot Plate Test	172
Effect of HMC on Von Frey Hair Test	173
Effect of HMC on Tail Immersion Test	174
Effect of HMC on Tissue Biomarker Changes	175
DISCUSSION	176
CONCLUSION	179
CONFLICT OF INTEREST	179
ACKNOWLEDGEMENTS	179
REFERENCES	179

SUBJECT INDEX	188
----------------------------	-----

PREFACE

The present book is about pain, a vital part but an unwelcome guest in the corridors of human health. If we count the toll of human sufferings, the pain is the forefront perpetrator. It is metastasizing and has tethered directly or indirectly to almost every disease or morbid condition. Its realisation is different by anaesthesiologist on pre-operative condition, neurologist on migraine or headache, rheumatologist on arthritis and oncologist on cancer, however, complex and distinctive appraisals are proclaimed by different patients.

Scientists have exposed constellation of factors and started hunting down all those culprits which contribute but are still absconding from the scene of pain. The physiological, biochemical and genetic role in human pain has been delved, discussed and disseminated in clinical literature but many concerns are still to be unravelled.

This compendium, "Pain: Causes, Concerns and Consequences" is aimed to assimilate and harness scholastic knowledge from the scientists and researchers of high repute, who have been working in this domain of pain research. This treatise has positively brought state of the art knowledge in relation to prognosis and prophylactic measures of pain, which we surmise to be a valuable volume.

In the first chapter Dr. David shares his experiences of understanding pain as a clinician. He trudges along his memory lane and discusses the interdependence of clinician and researcher in the search of indepth perception of explained and unexplained pain. His professional journey as a special orthodontist proffers a novel way of tackling pain by employing not only classical but psychological ways and means.

Dr. Bai Chuang Shyu discussed that central post -stroke pain (CPSP) involves three hypotheses: central disinhibition, central imbalance and central sensitisation, which do not conflict with each other.

He puts forth that, although, neural substrates of CPSP are diverse, but cortical pain matrix (contra lateral somatosensory cortex, bilateral mid and posterior insula, interior insula and posterior cingulate cortex) regulates pain processing in CPSP. He concludes that [¹⁴C] iodoantipyrine (IAP) data from the animal model of CPSP with lesions of ventrobasal complex of right thalamus indicate that during pain, significantly higher activation occurs in the medial prefrontal cortex (mPFC), interior cingulate cortex, thalamus, hypothalamus, amygdala and periaqueductal gray (PAG). He proposes that for, CPSP this novel idea of checking [¹⁴C] IAP may be used for pharmacological and non- pharmacological interventions of CPSP.

Third chapter emphasises the psychological issues in cardiac and non-cardiac chest pain. In emergency departments and intensive cardiac care units (ICCU), the most common symptoms of these patients are psychological stress, fear and anxiety. If remain unaddressed, these symptoms may lead to worst outcomes with severe ramifications. Psychotherapy especially cognitive and behavioural interventions can substantially lower the pain developed as a consequence of psychological distress.

Fourth chapter presents the facts and figures of several genes that participate in different phases of pain. Pain being a complex manifestation is perceived, processed and promulgated first and foremost through genetic endowment of the individual whereas, physiology, psychology, sociology and environment, later appear on the scene. It is acknowledged in this chapter that the idea of personal medicine for managing pain, based on the genetic profiling of the individual is possible in near future.

Dr Przekop writes about the causes and concerns of chronic non-cancer pain (CNCP) especially when coexisted with substance use disorder (SUD). He professes that, in formulating the treatment plan for CNCP and SUD the concomitant factors of one's psychology, sociology and physiology should be taken care of, so that the patient becomes an active participant in the treatment of his or her chronic pain.

Fifth chapter emerges out from a query that whether microRNAs (miRNAs) play role in pain pathophysiology and targeting them can be useful in managing pain. The chapter diligently explores the role and relevance of miRNAs in anti-nociceptive therapeutics. Apropos to the query, the chapter reveals that understanding the miRNA expression profile in almost every component of somatosensory system from peripheral neurons to higher central system, plays promising role in modulation of pain perception.

Dr Muthuraman investigates the analgesic potential of 7-hydroxy-4-methyl-coumarin (HMC) in acrylamide induced pain in rats. By conducting acrylamide induced nociceptive pain sensation and biochemical estimation, he documents that pre-treatment of rats with HMC and cyclosporine; ameliorate the acrylamide induced changes in biochemical and behavioural parameters in dose dependent manner.

He suggests that this ameliorative effect of HMC is because of its antioxidant, anti-lipid peroxidative, calcium ion regulatory and mitochondrial permeability transition pore inhibitory action.

We are deeply indebted to Ms. ShalluKhullar for her extended help in style editing of the book. We extend our heartfelt gratitude to Mrs. Humaira Hashmi, Editor In-charge, eBook department and Editorial Manager Publications, Ms. Hira Aftab, Incharge Publications, Ms. Maria Baig, Manager Publications and especially Mr. MahmoodAlam, Director Publications,

Bentham Science publishers for their kind support, encouragement and help.

Dr. Puneetpal Singh

Department of Human Genetics
Punjabi University, Patiala.

Dr. Monica Singh

Department of Human Genetics
Punjabi University, Patiala.

List of Contributors

Andrew Chih Wei Huang	Department of Psychology, Fo Guang University, Yilan, Taiwan, Republic of China
Arunachalam Muthuraman	Neuropharmacology Division, Department of Pharmacology and Toxicology, Akal College of Pharmacy & technical Education, Mastuana Sahib, Sangrur 148002, Punjab, India
Bai Chuang Shyu	Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China
David S. Bassler	53 Bennetts Road Mountain River, Tasmania 7109, Australia
Harjot Dhillon	Department of Human Genetics, Punjabi University, Patiala, India
Hsiang-Chin Lu	Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, India
Jaspreet Kaur	Neuropharmacology Division, Department of Pharmacology and Toxicology, Akal College of Pharmacy & technical Education, Mastuana Sahib, Sangrur 148002, Punjab, India
Masoumali Masoumi	Professor of Cardiac Surgery, Bistoon Hospital, Kermanshah, Iran
Mozhgan Saeid	Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Muthusaamy Ramesh	Neuropharmacology Division, Department of Pharmacology and Toxicology, Akal College of Pharmacy & technical Education, Mastuana Sahib, Sangrur 148002, Punjab, India
Peter Przekop	Betty Ford Center, Rancho Mirage, CA 92270, USA, Departments of Pediatrics, Neurology, and Psychiatry. Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
Puneetpal Singh	Department of Human Genetics, Punjabi University, Patiala, India
Saeid Komasi	Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Yogita K. Adlakha	Cellular and Molecular Neuroscience, National Brain Research Centre, Manesar-122051, India

DEDICATION

Qwt'Rctgpw'cpf'F gct'Uqp'Dwpp{

Pain: A Clinician's Journey

David S. Basser*

22 High Street New Norfolk, Tasmania 7140, Australia

Abstract: Pain is a percept: it is an unpleasant sensory and emotional experience, a product of the brain's abstraction that might be considered an activity mediated event: the activity being the message and pain the messenger warning of imminent or actual injury or imbalance yet to be avoided or resolved. There are no 'painful stimuli' that is stimuli that invariably elicit the perception of pain in all individuals and it is this highly individual and subjective nature of pain that makes it difficult to define and to treat clinically. The key to understanding and therefore appropriate treatment is in deciphering the message. Recognising and respecting the interdependence of both the clinician and researcher in the search for deeper discernment proffers the potential for synergistic evolution in understanding and treatment with the promise of bringing relief to many sufferers of both explained and unexplained pain.

Keywords: Allodynia, Central sensitisation, Chronic pain, Clinical application, Clinical experience, Global syndrome, Idiopathic pain, Neural activity, Neuroplasticity, Occlusion, Orofacial pain, Pain, Patient centred, Persistent pain, Precision medicine, Psychoneuroimmunology, Psychosocial, TMD.

INTRODUCTION

Pain and suffering are integral to the transformative journey that is life. In humans pain may be initiated at the physical, psychosocial and/or spiritual level(s) and experienced at any one or combination of these levels.

* **Corresponding author David S. Basser:** Specialist Dentist, 22 High Street New Norfolk, Tasmania 7140, Australia; Email: dbasser@ozonline.com.au.

PART 1**Pain: a Clinician's journey**

There is an abundance of information in the scientific literature, the relevance of which is often beyond the scope of understanding of the general clinician. Likewise much of the clinical experience and effectiveness of the clinical generations is not part of the scope of conception of the general scientific researcher. In an age, demanding evidence based biomedicine, it would seem prudent to afford equal respect to the expertise developed in both clinical and research areas and acknowledge, through action, their interdependence to affect mutual synergistic evolution. This then may re-establish the balance, as called for by Besedovsky and Del Rey [1], between deduction and induction, analysis and synthesis (the essence of science) in biomedicine. Benjamin Moffett [2], Professor of Orthodontics at the University of Washington, School of Dentistry, afforded much respect in 1978: he stated, “As a professional scientist working in dentistry for the past 25 years, I have been impressed by the progress, which clinicians make with time in solving their patient’s problems. These advances are often accomplished empirically without prior benefit of needed biological data from non-clinicians. Such gains are hard fought victories and are slowly recognized both within and outside the profession for several reasons. They are usually founded on individual clinical experience – a process that is not easily evaluated by others. Also the biological significance of these clinical advances is often obscured by the emphasis which clinicians naturally place on clinical procedures. But for those who are willing to learn from the trials and errors of others, the resulting insights are rewarding ... Because I am not a clinician ... you may be wondering why I opened the paper with a purely clinical observation. My reason is that when asked for a biological appraisal ... I ask the clinician in turn ‘Does it work at the clinical level?’ Whether a procedure or concept succeeds clinically is a big factor in determining its biological validity ... my question should (then) be (not if but) ‘Why does it work?’”

I come to an understanding of pain having directly experienced two generations of clinical expertise in resolving patient’s acute and chronic orofacial pain, the latter usually being classified as “idiopathic” or, to quote Woolf [3], “unexplained

clinical pain”.

In 2002, I embarked on a scientist's path in the quest for an explanation of the “unexplained”. In November 2004, whilst completing a library based research paper in fulfilment of a unit for the formal neuroscience degree in which I was enrolled, I happened upon a theoretical explanation; the result of a distillation of the scientific literature combined with the experience and deliberations of two generations of clinicians. In line with Moffett's commentary, the paper (in a slightly updated form) did not find publication until 2012 [4]. Here, I present an updated theoretical understanding of pain based upon the clinical and scientific experience of the intervening years.

Pain; A Theoretical and Applied, Integrative Clinical and Research Understanding

“The sensation we call pain – pricking, burning, aching, stinging, and soreness - ... is a submodality of somatic sensation like touch, pressure and position sense and serves an important protective function. It warns of injury that should be avoided or treated. Pain is a percept: it is an unpleasant sensory and emotional experience... a product of the brain's abstraction and elaboration of sensory input... there are no ‘painful stimuli’ – stimuli that invariably elicit the perception of pain in all individuals”... thus... “The highly individual and subjective nature of pain is one of the factors that make it difficult to define and to treat clinically” [5].

All pain, might be considered an activity mediated event: the activity being the message and pain the messenger warning of imminent or actual injury or imbalance yet to be avoided or resolved. The key to understanding, and therefore appropriate treatment, will be in deciphering the message. When attempting to do so, it should be remembered that pain is not a site specific phenomenon, but a perception of activity mediated by the neural pain matrix which comprises a vast interrelated network of peripheral and central neural components acting as a functional unit [4].

From a neuroscientific perspective there are two aspects to consider, the pain threshold and the level of activity. The pain threshold might be thought of as an activity switch, the parameters of which are unique to each individual, being

Functional Brain Circuitry in Central Post-stroke Pain

Andrew Chih Wei Huang¹, Hsiang-Chin Lu² and Bai Chuang Shyu^{2,*}

¹ *Department of Psychology, Fo Guang University, Yilan, Taiwan, Republic of China*

² *Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China*

Abstract: Central post-stroke pain (CPSP) results from lesions or dysfunction of the spinothalamocortical pathway. Pathophysiological mechanism of CPSP may include contralateral somatosensory cortex or bilateral mid- and posterior insula, anterior insula, posterior cingulate cortex and spinothalamocortical pathway. Our [¹⁴C] iodoantipyrine data from animal model of CPSP indicated that significantly higher activation occurs in the medial prefrontal cortex (mPFC), anterior cingulate cortex, thalamus, hypothalamus, amygdala and periaqueductal gray (PAG). We propose a neural correlation hypothesis of CPSP, in which the mPFC-amygdala pathway, hypothalamus and PAG interact with each other and the spinothalamocortical pathway, resulting in the manifestation of CPSP symptoms. These symptoms can include depression, anxiety, motor disturbances and cognitive dysfunction in thalamic stroke patients, in addition to CPSP. Alterations in different brain activation and circuitry connections in CPSP may help in understanding the pathophysiological mechanisms underlying multiple aspects of CPSP symptoms. Such novel ideas may be applied to develop pharmacological and non-pharmacological interventions for CPSP.

Keywords: CPSP, Nociceptive stimuli, Spinothalamocortical pathway.

INTRODUCTION

Based on the definition of the International Association for the Study of Pain, central pain is attributable to primary lesions or dysfunction of the central nervous system [1]. The clinical characteristics of central pain are severely confounded by

* **Corresponding author Bai Chuang Shyu:** Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China; Email: bmbai@gate.sinica.edu.tw

the characteristics of peripheral pain, with the exception of the location of neuropathic damage in the central or peripheral nervous system [2]. Distinguishing between central pain and peripheral pain is important, in which damage or dysfunction of spinothalamocortical mechanisms is critical for central pain but not peripheral pain [3]. Despite the distinctions between central and peripheral pain, “deafferentation pain” is suggested to be common to both central and peripheral pain. Both types of pain involve deficits or decreases in sensory inputs to the nervous system; thus, they share some clinical characteristics [4]. The essential characteristics of central pain consist of dysesthesia or paresthesia, persistent or paroxysmal pain, and spontaneous or evoked pain. When central pain is caused by stroke, with damage or dysfunction of the central nervous system, central pain is referred to as central post-stroke pain (CPSP) [5].

1. CLINICAL SYMPTOMS OF CENTRAL POST-STROKE PAIN

Previous studies thought that CPSP results from thalamic lesions, referred to as thalamic symptoms [6]. However, recent findings have shown that CPSP is also associated with extra-thalamic lesions [7]. The prevalence of CPSP is uncertain. Klit *et al.* [6] reported prevalence between 1% and 12% whereas another study reported it to be 8-35% [5]. Although the prevalence of CPSP is diverse, it appears to be > 8% in stroke patients. The cardinal symptoms of CPSP include pain that is attributable to impairments in the spinothalamocortical pathway. This impairment of the spinothalamocortical circuitry is resulted in the neuropathic pain. In general, peripheral sensitization and central sensitization are two major neuronal mechanisms underlying the neuropathic pain. Previous evidences have reported that the noxious stimuli may sensitize the peripheral nervous structure resulted in sensitization development, wind-up or expansion of receptive fields of nociceptive neurons. Moreover, molecules such as prostaglandin and bradykinin have been seen as pain mediators to affect peripheral sensitization and peripheral pain. These molecules are resulted from the tissue damage or inflammation, and they are suggested to involve peripheral sensitization and hyper-activation from peripheral signaling of sensory neurons. CPSP is primarily due to the central

sensitization mechanism. Hyper-excitability of the central neuronal circuitry in the central pain involves abnormal neurotransmission of glutamate, substance P and nitric oxide. Central sensitization can be reduced by the brain GABA receptor agonism or the glutamate (such as NMDA) receptor antagonism. GABA or NMDA categories of drugs have been developed to treat CPSP patients. For example, carbamazepine, which was a typical antiepileptic drug and GABA receptor agonist, are frequently used to reduce abnormal hyperactivity for the involvement of central neuronal disinhibition. Ketamine is another treatment method for CPSP that is one of NMDA receptor antagonists. It was evident that intravenous ketamine administration can effectively reduce the CPSP symptom. In addition, oral administrations of ketamine can alleviate dysphoria when using to combine with oral diazepam. On the other hand, pain perception may be spontaneous or evoked. In spontaneous pain, some cases present a continuous way and some are shown a paroxysmal way. Regardless of continuous or paroxysmal conditions, patients with CPSP often suffer from sensations of burning, aching, squeezing, pricking, lacerating, shooting, throbbing, heaviness, and cold. Evoked pain in CPSP is caused by nociceptive or non-nociceptive stimuli. Nociceptive stimuli can induce hyperalgesia in punctuate and thermal conditions. Non-nociceptive stimuli elicit allodynia in thermal, static, and dynamic conditions. Therefore, allodynia and hyperalgesia are likely important features of CPSP symptoms.

In addition to pain symptoms, some psychological, social, and physiological functions are also impaired in patients who suffer from stroke hemorrhage and consequently CPSP [8]. For example, previous studies showed that stroke hemorrhage patients may present motor dysfunction and clinical depression [9, 10]. Patients with stroke hemorrhage have been shown to present affective and apathetic symptoms, such as anxiety and depression [11]. Moreover, clinical data have shown that patients with thalamic lesions exhibited cognitive dysfunction [12]. After focal thalamic lesions, explicit memory and implicit memory can also be impaired [13]. Moreover, amnesia was present following thalamic hemorrhage [14]. Quality of life and motivation also deteriorate after stroke. Patients with CPSP may present blunting of thought processes that affects mood and intellect and produces neurotic tendencies [15]. Additionally, patients with CPSP have an

The Role of Psychological Factors in Cardiac and Non-Cardiac Chest Pain

Masoumali Masoumi¹, Mozhgan Saeidi² and Saeid Komasi^{2,*}

¹ *Cardiac Surgery, Bistoon Hospital, Kermanshah, Iran*

² *Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran*

Abstract: Chest pain as a common symptom in general population is considered to be the second most common cause of presentation to emergency departments of medical centers. Such pains are categorized broadly into cardiac chest pain (CCP) vs. non-cardiac chest pain (NCCP). In patients with cardiac diseases, the main symptoms of psychological reactions to pain include psychological stress, fear and anxiety, pain resulting from anxiety, and anxiety and depression as a result of pain. Furthermore, there is a relationship between perceived psychological factors and the psychological distress, and sustained NCCP could lead to the development of depression, stress and low mental quality of life. Controlled clinical trials on treating CCP and NCCP have shown that these relatively extensive interventions have been effective in reducing psychological distress, periods of chest pain frequency, and lowering functional problems.

Keywords: Angina pectoris, Cardiac chest pain, Cardiovascular diseases, Cognitive - behavior therapy, Non-cardiac chest pain, Psychological distress, Psychological factors, Psychotherapy.

INTRODUCTION

Since life-threatening events in patients with or without established cardiovascular diseases (CVDs) occur suddenly, chest pain experience could be horrifying for

* **Corresponding author Saeid Komasi:** Cardiac Rehabilitation Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Shahid Beheshti Boulevard, Kermanshah, Iran; E-mail: S_komasi63@yahoo.com

anyone [1]. Chest pain as a common symptom in general population is considered to be the second most common cause of presentation to emergency departments (ED) of medical clinics and hospitals [2]. In the US, six million patients present to ED annually. This imposes over eight billion US\$ on healthcare system [3]. Chest pain, with a life time prevalence of 39%, affects the quality of life of suffering patient severely and results in decreased working ability, physical exercise and serious sleep problems [4 - 7]. Chest pain, especially as it may herald serious cardiac conditions like heart attack, cause nervousness and consequently lead in apparent complaining by patients [8]. Chest pain presents itself in various forms such as paresthetic sensation, hot flashes, tingling, pressure sensation, and choking. It also varies in terms of duration and severity [9]. Such pains are categorized broadly into cardiac chest pain (CCP) vs. non-cardiac chest pain (NCCP).

CARDIAC CHEST PAIN (CCP)

Cardiovascular diseases (CVDs), as one of the most common conditions, are responsible for disability in 151 million patients and death in 17 million cases of the world population. Even though 14% of disabilities and 30% of mortality cases in developed countries are attributed to CVDs, about 82% of disabilities and 75% of death cases in developing countries are the result of such diseases [10]. One of the symptoms of cardiac disease is chest pain which is considered as one of the most prevalent cause of presentation of patients to cardiovascular clinics [11]. CCP are usually the result of acute coronary syndrome (ACS), myocardial infarction (MI) or ischemia, aortic dissection, pericarditis, cardiac arrhythmias, anxiety and panic attacks.

The pain of MI, myocardial ischemia, pericarditis, and greater vessels disease are considered as one of the most common causes of CCP. The pain of MI or myocardial ischemia happens when the required oxygen of the myocardium is not supplied. But infectious pericarditis pain always involves the surroundings of the pleura and cause pleuritic pain in patients. This pain aggravates with inspiration, coughing, and bodily position change. However, in patients with vascular diseases, acute aortic dissection causes a sudden, tearing, and severely distressing pain [12]. Pain is a mental phenomenon associated with unpleasant feelings and

causes distress. Pain-related complaints are the most common symptoms experienced by patients [13].

Epidemiology

Annually, seven million Americans present to ED because of acute chest pain. About 15-25% of such presentations are due to CVDs [12]. The prevalence of angina pectoris increases with aging in both males and females and it is estimated that 2-4% of adult population in the Europe experience CCP [14]. According to Modi *et al.* (2015), of patients who admit in ED because of chest pain, less than 50% are discharged in a short time and only 7.2% of those who are admitted have CVDs [15]. In another study, it has been reported that in 9.6% of the cases, the cause of chest pain is CADs [16].

Etiology

CCP is the result of decreased blood supply by coronary arteries or increased demand for oxygen by the myocardium [17]. The most common cause of acute chest pain in patients with CVDs is MI or myocardial ischemia and happens when enough oxygen is not supplied to the heart [12]. This pain which can be continuous or intermittent is known as angina pectoris. Angina can be affected by factors other than cardiac diseases such as psychological factors.

Cardiac Chest Pain and Mechanism of Pain

Chest pain, while having many etiologies, is generally considered to be most lethal when related to a cardiac cause [18]. Cardiac chest pain or angina pectoris can be either acute or chronic and usually is a result of imbalance between myocardial oxygen supply and myocardial oxygen demand. Atheroma formation and atherosclerotic plaques seem to affect coronary flow, given that multivessel flow-limiting obstructions are observed in patients with chronic coronary syndrome. In addition, morphological changes of diseased arteries related to significant atherosclerosis, such as vascular remodeling may also result in stable angina or claudication [19].

Although, angina pectoris has a variety of physiological correlates, including the type of triggering activity, the severity of ischemia or ventricular dysfunction,

Genetic Explorations of Pain

Harjot Dhillon and Puneetpal Singh*

Department of Human Genetics, Punjabi University, Patiala-147002, India

Abstract: Pain is the most prevalent form of human health malady which, if remain unaddressed, exerts formidable impact. Pain research has tried hard to unravel the possibilities in the direction of diagnosis and management of pain conditions, but knowledge of genetic consequences of pain is still in infancy. During pain, sensory input is realized, processed and regulated, first and foremost through ones genetic composition and then different characters of physiology, psychology, sociology and environment come in the scene. The present exposition demonstrates the precise details of various genes and genetic variants that participate in different phases of pain and pain conditions, disseminating an idea that in future, diagnosis and treatment of pain by harnessing indepth genetic knowledge has startling revelations in store for us.

Keywords: Chronic pain, Conduction, Genes, Modulation, Synaptic transmission, Transduction.

INTRODUCTION

Pain is a complex sensation where sensory, affective and cognitive dimensions of pain alongwith parallel neural networks in brain are associated with constellation of factors. Though pain occurs to show protective gesture, but when it surpasses threshold, exerts debilitating effect upon health and triggers concomitant physiological and psychological concerns of perilous ramifications. Right from the activation of primary afferent nociceptors upto the cortical processing of the pain in the higher regions of the brain, pain trajectory can be dissected into transduction, conduction, synaptic transmission and modulation.

* **Corresponding author Puneetpal Singh:** Department of Human Genetics, Punjabi University, Patiala; Email: singh.puneet@rediffmail.com

Besides, environmental, behavioral and psychological risks involved, all these stages of pain sensitivity, severity and analgesic responses are mediated by different sets of genes and genetic variants.




Fig. (1). Showing different phases of pain

1. TRANSDUCTION

Transduction marks the cardinal process for the pain realization. It involves detection of noxious stimuli by the peripheral nociceptors by sensing various substances such as substance P, bradykinin, *etc.* leading to the depolarization of the neurons causing generation of a receptor potential [1].

Heat Pain

The nociceptors detect four major types of noxious stimuli namely; heat, cold, mechanical and chemical. The detection of these various types of stimuli is further regulated by numerous genes. Amongst the most studied one in relation to heat related sensitization are the transient receptor potential (TRP) family genes. TRP

family is a calcium gated channel protein family comprising 6 subfamilies; TRPA, TRPV, TRPM, TRPML, TRPP and TRPL. While the majority of TRP gene family members detect specific types of noxious insults, some of them are polymodal in function. A class of TRP gene family; TRPV1 is activated by both heat and capsaicin found in hot chilli pepper [2]. It is highly associated with detection of thermal, mechanical and pH shifts. The polymodal function of TRPV1 has been confirmed by various gene knockouts, siRNA knockout and inhibition studies [3]. In human, TRPV1 Met315Ile and Ile585Val polymorphism has been examined and Met315Ile is found to be associated with greater susceptibility to chronic neuropathic pain [4]. TRPV1 acts in close amity with Protein kinase beta type II (PKC β II), as the activation of the latter by TRPV1 causes phosphorylation of Thr705, setting the pain and itch thresholds below normal ranges [5]. TRPV1 also regulates calcitonin gene related peptide (CGRP) functioning as TRPV1 knockouts show enhanced metabolism and longevity due to suppression of CGRP activity [6]. The TRPV1 knockout shows reduced thermal sensitivity while TRPV2 knockout shows normal function. Surprisingly, 1911A>G (rs8065080) polymorphism is found to be associated with cold hypoalgesia, less heat, pin prick and mechanical hyperalgesia, whereas, 1103C>G (rs2222747) is associated with reduced cold hyaesthesia. None of the TRPV polymorphisms give impaired functions, suggesting its indirect linkage to pain *via* somatosensory abnormalities than direct function in pain [7]. In a complex manner, inflammatory mediator bradykinin enhances mechanical pain through Purinoreceptor 2X (P2X_{2,3}) receptors mediation, and upregulates TRPV1 activation and Adenosine triphosphate (ATP) production *via* keratinocytes, Nerve growth factor (NGF) signaling *etc.*, thus causing mechanical hyperalgesia [8, 9]. However, inflammation induced hyperalgesia involves several other inflammatory mediators besides bradykinin alone [10].

Following the footprints of TRP gene family, Anoctamin 1(ANO1), a calcium activated chloride channel senses heat related pain detection. It depolarizes the neuron, causing generation of action potential. Animal studies confirmed its role in propagating heat stimuli, but not mechanical noxious stimuli by gene knockout, tail flick tests and chemical inhibition methods [11, 12].

Non-Pharmacological Treatment Options for Coexisting Chronic Non-Cancer Pain and Substance Use Disorder

Peter Przekop^{1,2,*}

¹ *Betty Ford Center, Rancho Mirage, CA 92270, USA*

² *Departments of Pediatrics and Psychiatry, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA*

Abstract: Chronic non-cancer pain (CNCP) presents significant challenges to physicians and when combined with co-occurring diseases such as substance use disorder (SUD) the challenge becomes magnified. It is important that the physician realizes that both CNCP and SUD are diseases of the brain, mind, body, and spirit and, therefore, consideration of the whole person and their life experience is essential. In formulating a treatment plan, the physician should remember the cognitive and emotional changes that have occurred as a result of the disease's effect upon the and mind. The proper treatment of the patient should also include treatment of chronic stress and its consequences. The physician should be aware of the alternative modalities such as mind-body, psychosocial, and technology based treatments. Many are available to the patient locally and can also be accessed through the internet. Physicians who treat complex CNCP patients should begin to implement these modalities in a comprehensive treatment plan that restores balance to the patient with CNCP and SUD and allows the patient to become an active participant in their care.

Keywords: Brain, Chronic non-cancer pain, Cognition, Mind-body therapy
Nociceptor, Substance use disorder.

* **Corresponding author Peter Przekop:** Betty Ford Center, 39000 Bob Hope Drive, Rancho Mirage, CA 92270, USA;
E-mail: pprzekop@llu.edu

INTRODUCTION

Many physicians are faced with difficult challenges when treating chronic non-cancer pain (CNCP) and the many occurring processes that it is associated with. This situation has become somewhat easier since new research that has occurred over the last two decades has made it clear that CNCP is a fundamentally different disease process when compared to acute pain. Indeed, CNCP is a disease process in which the brain has transformed, reorganized, and has become capable of generating pain spontaneously [1 - 3]. "It is now clear that CNCP is very complex which explains why the simplistic Cartesian approach in which a peripheral nociceptive input is treated is ineffective [4 - 6]. Effective treatments must consider the mind, brain, body, and spirit [7]. The current lack of such treatments has left many physicians in a difficult position especially those who treat patients with CNCP and co-occurring substance use disorder (SUD) [8].

This apparent gap in treatment options can be filled by alternative treatment options which range from mind-body therapies, to psychosocial treatments, to technology based therapies, all of which can offer healing to complex CNCP patients. These treatments are effective and popular because they support healing as opposed to chronic disease management, add balance, and well-being, and are devoid of adverse effects [7]. An estimated 62% of Americans take advantage of them [9, 10].

The Scope of the CNCP Problem

CNCP confers considerable suffering to many and is currently at epidemic levels [11]. An estimated half of all patients with SUD also have CNCP [12]. Patients with CNCP and SUD are very difficult to treat with conventional Western medicine, generally pharmacologic methods because they seek help for much more than just physical pain [13, 14]. Most suffer from co-occurring anxiety, symptoms of depression, chronic stress, multiple problems, and the culmination of adversity they have and do suffer from [15]. Most of these patients will be improperly selected for chronic opioid therapy in an attempt to relieve their suffering. However, historically, they have been excluded from opioid clinical trials [16] and thus, there is virtually no evidence to guide opioid-based treatment

choices [17]. To complicate matters, it is essential that CNCP is adequately treated in these patients because 60% of them report that pain significantly contributes to the development of SUD [18]. Moreover, effective treatment has been shown to normalize the changes which occur in the brain as a result of CNCP [19].

The Patient with CNCP and SUD

When approaching the patient with CNCP and SUD it is important for the physician to realize that the brain, mind, body, and spirit have been transformed and reorganized. The structural, functional, and connectivity changes of the brain have been extensively reported [20 - 22]. The reorganization of neural networks involved in goal-directed behavior, attention, internal surveillance, emotional regulation, and the ability to enjoy natural rewards have all resulted in significant changes [21] in the patient's ability to think, regulate emotions, regulate behavior, and maintain a positive outlook [23, 24].

Patients with CNCP and SUD have biased acquisition and processing of information that distorts thinking and continues to activate and sustain both disease states. The patient has lost attentional control and attention has been captured by the pain signal which makes it difficult to disengage attention from drug related cues. This results in a bias towards pain-related and drug-related cognitions. In addition, self-referential thought focuses on poor health and poor well-being further contributing to a loss of emotional regulation. Therefore, emotions are negatively valenced and thinking is skewed towards prolonged suffering, poor self-efficacy, pain catastrophizing, and fear of future pain [25].

These factors manifest in the patient as increases in the perception of pain and increases in the areas of the body in which the pain manifests. On days in which the above symptoms are especially severe the patient's perception of physical pain worsens. All is exacerbated by increases in acute and chronic stress.

Patients with both CNCP and SUD report high levels of current suffering and 96% of these patients report a history of unresolved adversity [17, 23, 26]. This results in a dysregulated chronic stress response [27, 28]. Patients display poor coping and report a lack of optimism [25]. In approaching these patients all of

MicroRNAs: The Tiny Robust Players Unraveling the Multifaceted Channels of Pain

Yogita K. Adlakha*

Cellular and Molecular Neuroscience, National Brain Research Centre, Manesar-122051, India

Abstract: Pain is a debilitating condition which is the leading cause of cognitive, mood and anxiety disorders. It is one of the major medical burdens on human health which obstructs the quality life of a person as the appropriate therapeutic solution is not available. Due to advancement of new genomic technologies, it is now possible to view genome wide changes during chronic pain in different cell types from the somato-sensory system to the neurons in central nervous system. Tremendous research over recent years has enlightened the magical potential of small non-coding RNAs, mainly microRNAs in modulating numerous pathophysiological processes including proliferation, apoptosis and oncogenesis. They target a wide range of molecules and refine their protein output and thus, fine tune distinct cellular processes including pain signaling. Recently, animal models depicting inflammatory and neuropathic pain and patient subjects complaining distress due to pain have shown deregulations of miRNAs in affected tissues and systemic circulation. Although various painful conditions *viz.* spinal cord injury, peripheral nerve injury, cancer and inflammatory diseases have been recognized with genome-wide changes in microRNA signatures, yet the gene regulatory networks underlying pathological significance of individual microRNAs are sparsely studied. Hence, this chapter summarizes the latest findings addressing the role of microRNAs in various inflammatory or neuropathic pain conditions. How can miRNA research be expedited in revealing new aspects of pain pathophysiology is also addressed. The chapter also uncovers the novel potentials of miRNAs as well as roadblocks in the path of miRNA based anti-nociceptive therapies.

Keywords: DRG, miRNA, Nociceptive pathway, Pain, Spinal cord, TG.

* **Corresponding author Yogita K. Adlakha:** Cellular and Molecular Neuroscience, National Brain Research Centre, Manesar-122051, India; E-mail: yogita@nbc.ac.in

INTRODUCTION

Although pain is one of the fundamental alarming systems of the body yet chronic pain may devastate the quality of one's life, leading to disturbances in the cognitive and emotional functions. Thus, human disorders associated with the chronic pain including osteoarthritis (OA), post-herpetic neuralgia, diabetic polyneuropathy and migraine represent a large socioeconomic burden. Although recent research has provided fundamental insights into pathological pain, yet effective therapeutic treatments are least available till date. In recent years, accumulating reports have introduced a novel entity in pain that is known as microRNAs (miRNAs) for being small, functional non-coding RNAs in nature that have been playing an instrumental role in regulating pain-processing in various pain settings ranging from experimental models to clinical pain disorders [1 - 4]. These studies have provided the basic understanding for the development of microRNA therapeutics for the treatment of pathological chronic pain in future. The main objective of this chapter is to discuss various implications of miRNAs in pain and to explore ways to expedite the miRNA research in pain pathophysiology. Attention has also been paid to exploring opportunities for the development of miRNAs as a therapy for chronic pain.

Pain

Pain is such an unpleasant feeling which cannot be described in words. It is an obnoxious sensation that is not only associated with sensory experience due to actual or potential tissue damage but also with the elements which alter cognitive and emotional circuitry [5]. Pain can be categorized into two types depending upon the length of stimulus: acute and chronic. Acute pain lasts till the applied stimulus and resolves promptly, thus functions as a central alarming system for the body and protects from damage [6]. However, chronic pain is devastating and outlasts the period of initial injury and thus reduces patient's quality of life. Therefore, there is an urgent call for effective clinical intervention for such unfortunate pain. However, till date, therapeutic solutions are distant from sight due to the hindrance by large numbers of mediators and signaling pathways in the etiology of pain and presence of functional redundancy between them [6]. Further, pain can be divided into two groups depending upon the type of stimuli:

Nociceptive and Neuropathic pain. Nociceptive pain is initiated by signals from damaged tissues or injury which get transferred through peripheral nerves to the brain *via* the spinal cord. This type of pain works as an alerting system for the organism and prepares organism against potential damage. Mostly back, leg and arm pains are nociceptive pains. However, aberrations in somatosensory system can cause damage or disease in the nervous system which is the root cause of neuropathic pain [7]. Chronic neuropathic pain is completely pathological and does not have beneficial aspect. This pain occurs after a stroke or after cutting of nerves and include shingles and diabetic peripheral neuropathy.

The nociceptive pain signaling initiates upon the detection of a nociceptive stimulus by nociceptors. These nociceptors are the primary neurons that have their cell bodies in dorsal root ganglion (DRG) or trigeminal ganglion (TG). However, their peripheral axons sense this stimulus and send this information to DRG or TG *via* their cell bodies. The information is relayed from DRG or TG to the spinal or medullary dorsal horn *via* primary sensory neurons to secondary neurons [5]. Interaction between excitatory and inhibitory inter neurons, glial cells and descending axons from the brainstem form the complex circuits in the dorsal horn, and then process this information and relay the processed information to the higher brain areas which are mainly involved in pain sensation and associated emotions [8, 9]. Somatosensory cortices, prefrontal cortex, amygdala, insular cortex and anterior cingulate cortex form higher brain areas where pain is perceived and sensory and emotional processing of pain occurs [10]. Thus, chronic pain can negatively affect important brain functions including cognition and mood and hence, it is also associated with mood, comorbid cognitive and anxiety disorders [11].

MicroRNA

MicroRNAs (miRNAs) are the small, non-coding pieces of RNA, which were once misunderstood as cellular detritus, have now popped up as master players in the regulation of gene expression in the past decade. MiRNAs comprise a novel class of endogenous, evolutionarily conserved, non-coding single-stranded RNAs of ~19-25 nucleotides in length which mainly operate at post-transcriptional level. They were first discovered in *Caenorhabditis elegans* and since then they have

The Ameliorative Potential of 7-Hydroxy-4-Methylcoumarin in Acrylamide Induced Neuropathic Pain *via* Improving of Mitochondrial Function in Rat

Jaspreet Kaur, Arunachalam Muthuraman* and Muthusamy Ramesh

Neuropharmacology Division, Department of Pharmacology and Toxicology, Akal College of Pharmacy & technical Education, Mastuana Sahib, Sangrur 148002, Punjab, India

Abstract: The present study was designed to investigate the analgesic potential of 7-hydroxy-4-methylcoumarin (HMC) in acrylamide induced neuropathic pain in rats. Acrylamide (30 mg/kg, *i.p.*; once in three days, for 24 consecutive days) was administered for inducing neuropathic pain. The acrylamide induced nociceptive pain sensation, *i.e.*, acetone drop, plantar, hot plate, Von Frey Hair and tail immersion tests have been assessed at different time intervals, *i.e.*, 0, 6, 12, 18 and 24th day. Furthermore, the biochemical estimation, *i.e.*, thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH), total calcium, cytochrome c oxidase activity and ATP content levels were estimated from the sciatic nerve tissue sample on 24th day. The HMC (10 and 20 mg/kg, *p.o.*) and cyclosporin A (CsA, 50 µM/kg; *p.o.*) was administered for 24 consecutive days, one hour before each injection of acrylamide. The treatment of acrylamide resulted in significant ($P < 0.05$) changes of behavioral and biochemical changes. Pretreatment of HMC ameliorate the acrylamide induced changes of behavioral and biochemical parameters in a dose dependent manner. These results are similar to that of CsA treated group. Based on these findings, it may conclude that, HMC possesses the potential ameliorative effect against acrylamide induced neuropathic pain, it may be because of its therapeutic potential of anti-oxidant, anti-lipidperoxidative, calcium ion regulatory and mitochondrial permeability transition pore inhibitory action.

* **Corresponding author Arunachalam Muthuraman:** Neuropharmacology Division, Department of Pharmacology and Toxicology, Akal College of Pharmacy & technical Education, Mastuana Sahib, Sangrur 148002, Punjab, India. E-mail: arunachalammu@gmail.com

Puneetpal Singh (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

Keywords: 7-hydroxy-4-methylcoumarin, Acrylamide, Adenosine triphosphate, Allodynia, Calcium, Cyclosporin A, Cytochrome c oxidase, Electron transport chain, Hyperalgesia, Mitochondrial dysfunction.

INTRODUCTION

According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as “*pain initiated or caused by a primary lesion or dysfunction or transitory perturbation in the peripheral or central nervous system*” [1]. It is characterized by affecting the somatosensory system leading to produce the spontaneous pain, hyperalgesia, hypoesthesia, dyesthesia and allodynia [2]. In addition, the Food and Drug Administration (FDA) approved few drugs to manage the neuropathic pain syndrome, *i.e.*, anti-convulsants, anti-depressants, topical medicines and opioids [3, 4]. However, these medications give partially relief from the symptoms, induce wide spectrum of adverse effects and lack specificity. Thus, clinical usage of these drugs is limited in the management of neuropathic pain [5, 6]. The various animal models are well established for evaluating newer agents in the management of neuropathic pain syndrome. Acrylamide is one of the chemical methods for inducing neuropathic pain [7].

Acrylamide (prop-2-enamide) is an odourless white crystalline solid. It is widely used in various chemical industries for preparing polyacrylamides, water-soluble thickeners, sugar manufacturing, pesticide formulations, preparing permanent cement, press fabrics/plastic products, dyes and ore processing [8, 9]. It is also used as binding, thickening / flocculating agent, cosmetic preparation and gel electrophoresis process in pharmaceutical science [10, 11]. In addition, acrylamide was found in many roasted starchy foods [12 - 14]. Furthermore, it is present in black olives, prunes, dried pears, coffee, cocoa powder, roasted almonds, whole wheat bread and Pringles [14, 15]. The precise mechanism of acrylamide formation in foods remains unclear, but it is believed that, it is a byproduct of the Maillard reaction between asparagine and reducing sugars (*i.e.*, fructose and glucose) or reactive carbonyls at temperatures above 120 °C [16, 17]. Various studies have reported that, acrylamide is known to have potential neurotoxic effect [18, 19]. In fact, it produces the potential distal multifocal axonal degeneration, which is also known as “dying back” neuropathy. Generally,

“dying back” neuropathy is a progressive loss of peripheral and central neuronal axon which is observed in both humans as well as animal species [20 - 22]. Acrylamide (30 mg/kg, *i.p.*, for 24 consecutive days) induced neuropathic pain is one of the common experimental models of the neuropathic pain disorder. It is a clinically relevant model for neurotoxic chemical associated neuropathic pain and is widely accepted model due to its similar pathophysiological mechanism in humans as well as in rodents [20, 23].

Recently, various herbal constituents are employed in the management of neuropathic pain, *i.e.*, quercetin [24]; geraniol and curcumin [25]; safranal [26]; puerarin [27]; thymoquinone [28] which have been documented to produce the attenuation of neuropathic pain. Coumarin is one of the important flavonoid in herbal plants [24]. Higher concentrations of coumarin are present in *Dipteryx odorata*, *Anthoxanthum odoratum*, *Galium odoratum* and *Albizia antunesiana* [29, 30]. It has various pharmacological actions such as anti-diabetic [31], hepatoprotection [32], anti-coagulant [33], anti-tumor, and anti-fungal activity [34, 35]. Coumarin is one of the major constituents of the various herbal plants and has various therapeutic actions against ulcerative colitis [36], psychosis [37], thrombosis [38] and diabetes [39]. Recently, various reports have documented that, coumarin derivatives also possess the potential pharmacological actions, *i.e.*, anti-cancer [40], anti-inflammation [41] and improvement of learning and memory function [42]. The molecular mechanism of coumarin is known to have the free radical scavenger, *i.e.*, reactive oxygen species, reactive nitrogen species and reactive chlorine species, calcium channel blocking actions [43].

Furthermore, coumarin derivative is known to possess the potential action on mitochondrial functional regulation [44]. In addition, cyclosporine A is also documented to produce the neuroprotection *via* regulation of mitochondrial function by inhibition of mitochondrial permeability transition pore (MPTP) opening and release of cytochrome c [45]. Thus, cyclosporine A served as positive control in this study. Acrylamide is known to cause the mitochondrial dysfunction in the nervous system *via* opening of MPTP [46, 47]. Therefore, the present study has been designed to investigate the molecular mechanism and therapeutic potential of 7-hydroxy-4-methylcoumarin in acrylamide induced neuropathic pain in rats.

SUBJECT INDEX

- A**
- Acetone 161, 165, 171
- Acetylcholine 86, 88
- Acid 77, 78, 137, 161, 167, 168
 thiobarbituric 161, 167
 trichloroacetic 167, 168
- Acid sensing ion channel (ASIC) 77, 78
- Acrylamide 161, 162, 163, 164, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179
 administration of 169, 170, 171, 172, 173, 174, 175
 attenuated 171, 172, 173, 174, 175, 176
 change in 171, 172, 173, 174
 injection of 161, 164
- Acrylamide intoxication, day of 170, 171, 172, 173, 174, 175
- Acrylamide treatment 161, 177
- Activating central inhibition pain pathways 119
- Activation patterns, cortical 23, 25
- Activity of cytochrome 169
- Adrenaline 89
- Agranular insular 30
- Allele 76, 77, 79, 80, 81, 83, 84, 85, 87, 88, 89, 91, 92, 93, 94, 95
 minor 79, 84, 87, 88, 89
 short 93
- Allodynia 3, 7, 19, 20, 23, 24, 25, 33, 34, 115, 162, 165, 166, 173
 mechanical 33, 34, 165, 173
- Alterations, implicated miRNA 143
- Alter miRNA expression 146
- Ameliorative effect 178, 179
- Ameliorative Potential 163, 165, 167, 169, 171, 173, 175, 177, 179
- Amygdala-1 30, 31
- Amygdala-2 28, 30, 31
- Analgesics 78, 149, 161
- Aneurysms, aortic 46
- Angina pectoris 40, 42, 48, 50, 51, 52, 56
- Angiogenesis 43
- Animal miRNA targets 144
- Antagomirs 146
- Anterior cingulate cortex 17, 23, 25, 33, 34
- Anti-miRNA oligonucleotides (AMOs) 145, 146
- Anti-miRNA sequences 146
- Antinociception 34, 35
- Anxiety 17, 35, 36, 40, 41, 45, 47, 48, 49, 50, 51, 52, 54, 55, 56, 57, 58, 119, 120, 142
- Anxiety disorders 54, 126, 128
- Aortic dissection 41, 46
 acute 41, 46
- Aortic lumen 46
- Aortic wall 46
- Aortic wall circumference 46
- Argonaute proteins 130
- Assessment of behavioral pain sensation 165
- Atherosclerotic plaques 42, 47
- ATP content 167, 169, 176, 179
- ATP content levels 161, 175, 177
- ATP levels 169, 170
- Attenuating MiRNAs 145
- Axotomy 134, 137

Subject Index

B

Behavioral pain sensation 165
Binding, complementary 132
Biochemical evaluations 169, 170
Biogenesis 129, 130
Biogenesis of MiRNA 129
Biological processes 129
Blood pressure 45, 47, 51, 52, 83
Bone cancer 134, 135, 139
Bovine serum albumin (BSA) 164, 167, 169
Bradykinin 18, 74, 75, 82, 91
Brain activation 17, 27, 31
Brain activities 25, 27
Brain areas 22, 23, 24, 26, 27, 28, 31, 33, 35, 133, 142
Brain mapping in central neuropathic pain 25
Brain metabolism 23, 25
Brain's abstraction 3, 5

C

Caenorhabditis elegans 128, 129
Calcitonin gene related peptide (CGRP) 75, 83, 90, 92
Cancer, miRNA mediating 138
Cancer pain 138, 139
Canonical pathway 130, 131
Cardiac diseases 40, 41, 42, 49, 50, 52, 53
Cardiac events 49, 51, 52
Cardiovascular diseases 40, 41, 129, 146
Cellular uptake 145
Central disinhibition 20, 24, 35

Pain: Causes, Concerns and Consequences 3;

Central neuropathic pain 21, 25
Central sensitisation 3
Central sensitization 7, 8, 9, 18, 19, 20, 21, 22, 24, 35, 84
Central sensitization hypothesis 21, 22
Cerebral potentials 21
C-fiber-evoked pain responses 24
Chemical factors 44
Chest pain 40, 41, 42, 44, 46, 47, 48, 49, 50, 53, 54, 56, 57, 58, 59, 60
 acute 42
 cardiac 40, 41, 42
 cause of 42, 56
 lowering 59
 persistent 44, 46
 reducing 60
 severe 46
Chest pain experience 40
Chest pain frequency 40, 59
Chest pain symptoms 58
Childhood health assessment questionnaire (CHAQ) 84
Chronic constriction injury (CCI) 135, 136, 137, 141
Chronic idiopathic orofacial pain entities 6
Chronic non-cancer pain (CNCP) 111, 112, 113, 114, 115, 116, 118, 119, 120
Chronic widespread pain 91, 93, 94, 95
 higher 94
 risk regions for 91, 93
Cingulate cortex area 28, 29
Circulating miRNAs 134
Clinical symptoms of central post-stroke pain 18

- Cognitive-behavioral therapy (CBT) 48, 50, 51, 59, 117
 Cognitive dysfunction 17, 35, 36
 Cognitive therapy (CT) 53, 59, 60, 94, 117
 Cold chemical sensation 171
 Cold pain sensitivity alongwith 79
 Cold pain stimuli thresholds 87
 Cold pain tolerance 87
 Cold stimuli thresholds 87
 Complete adjuvant (CFA) 136, 138, 139
 Complex regional pain syndrome 143, 148
 COMT gene 92
 Contralateral thalamus 23, 24, 26
 Coronary artery bypass graft (CABG) 50, 51
 Coronary artery disease (CAD) 42, 48, 53
 Coronary epicardial 47
 CPSP symptoms 17, 19, 20, 24, 27, 34, 35, 36
 Cyclosporin 161, 162, 164, 170, 171, 172, 173, 174, 175, 176
 Cytokines 43, 90, 91, 177
 Cytoplasm 130, 131
- D**
- Depression 40, 58, 112, 120
 development of 40, 58
 symptoms of 112, 120
 Depression and anxiety 35, 47, 48, 58
 Diabetic neuropathic pain (DNP) 136, 137
 Diffusion tensor imaging (DTI) 25, 26
- Diprenorphine 23, 25, 26
 Dopamine 77, 79, 86, 88, 89, 91
 Dorsal root ganglion (DRG) 126, 128, 133, 134, 137, 138, 139, 141, 142, 146, 147, 148
 Dorsal spinal cord 141
 Dose dependant manner 173, 174, 175
 DRG neurons 139, 143
 Dysesthesia 18, 21, 22, 24
- E**
- Effect of HMC 173, 174
 Effect of HMC on acetone drop test 170, 171
 Effect of HMC on acrylamide 176
 Effect of HMC on hot plate test 172, 173
 Effect of HMC on plantar test 171, 172
 Effect of HMC on tail immersion test 174, 175
 Effect of miRNA of interest 144, 147
 Electrical pain intensity test 93
 Electrical pain stimuli thresholds 88
 Emotional distress 47, 48
 Emotional regulation strategies 51
 Endothelial dysfunction 43, 44, 46, 47, 48
 Endothelial injury 47
 Episodic pain 85
 Estimation of cytochrome 167, 169
 Evoked pain in CPSP 19
 Expression levels of miRNAs 137
 Extracellular miRNA 142, 143
 detected 143
 secreted 143

Subject Index

F

Facial inflammatory pain 136
Fatty acid amide hydrolase (FAAH) 76, 93
Fear of pain questionnaire 95
Fibromyalgia 7, 55, 84, 85, 89, 92, 93, 94, 95
Fibromyalgia impact questionnaire 94, 95
Fisher's Z-statistic 31, 32
fMRI study 23, 24
Food and drug administration (FDA) 162
Frey hair test 166, 173, 174

G

Generations, free radical 177, 178, 179
Genetic variants 73, 74
Global syndrome 3, 8
Glutamate 19, 86, 88
Granular insular cortex 28, 30

H

Haplotypes, high pain sensitivity 95
Health services 57, 58
Heat and cold pain 78
Heat pain stimuli 77
Herbal plants 163
High-throughput sequencing 149, 150
Hippocampus 28, 30, 142
HMC attenuates 178, 179
Homogenization buffer 168, 169
Hot pain tests 93
HPI, comprehensive 114

Pain: Causes, Concerns and Consequences 3;3

Human experimental pain 88

Human fMRI study 23

Humans cause pain 77

Hyperalgesia 19, 20, 24, 75, 76, 77, 79, 81, 83, 90, 95, 115, 162, 165, 166 induced 75, 77, 83, 95

Hypersensitivity, reversing pain 79

Hypertension 45, 46

Hypnotherapy 51, 52, 53, 60

Hypothalamus 17, 26, 27, 29, 32, 33, 34, 35, 36

I

Idiopathic orofacial pain entities 7

Idiopathic pain entities 7

Imperfect miRNA 131

Infralimbic cortex 28, 29, 31, 34

Interaction, miRNA-mRNA 132, 144

Interleukins 83, 91, 139

Intracellular miRNAs 144

Intravenous delivery 145, 148, 149

Ischemic heart disease (IHD) 43, 44, 47, 48

Ischemic heart disease and chest pain 44

Ischemic tourniquet pain test 85

K

Ketamine 19

L

Levels 3, 5, 6, 8, 11, 14, 79, 82, 83, 86, 90, 91, 92, 93, 94, 114, 121, 133, 141, 142, 143, 166

- cortical 91, 92
 - dorsal 90, 91
 - increased pain 93
 - increasing pain 83
 - net 6, 8, 11
 - pain threshold activation 8
 - peripheral 79, 82, 90
 - pressure pain 94
 - presynaptic 83, 86
 - raising pain 83
 - reduced pain 93
 - Lipid peroxidation 177, 178, 179
 - LNA-based miRNA inhibitors 146
 - Locked nucleic acid (LNA) 145
 - Long allele, carriers of 91, 93
 - Lumbar disc hernia (LDH) 84
 - Lumbar radicular pain 84
 - Lumber pain 85
- M**
- Maladaptive thoughts 117
 - Malondialdehyde 167
 - Mature miRNA duplex 130
 - Mature miRNA strand 131
 - Mature miRNA transcripts 130
 - Maximum voluntary isometric contraction (MVIC) 95
 - Mechanical hyperalgesia 75, 76, 82, 91
 - Medial lemniscus of spinal cord 21, 22, 24
 - Medial thalamus 20, 22, 23, 24, 25, 34
 - microRNA miRNA 150
 - Microvascular coronary dysfunction 43, 44
 - Midbrain gray matter 23, 26
 - miRNA and Target Interaction 131
 - miRNA binding sites 132
 - miRNA biogenesis pathway 131
 - miRNA Biology 140, 143
 - miRNA deregulation 134, 138
 - miRNA dysregulation, common 142
 - miRNA efficacy 149
 - miRNA expression 133, 136, 137, 141, 142, 145, 146, 147, 148
 - endogenous 145
 - miRNA expression changes 133
 - miRNA expression modulators 144
 - miRNA expression profile 133, 142, 148
 - miRNA functions 132, 133, 141, 144
 - underlying 144
 - miRNA-induced silencing 130
 - miRNA inhibitors 145, 146, 147, 148
 - miRNA levels 135, 137
 - miRNA manufacturing machinery 147
 - miRNA maturing enzyme Dicer 134
 - miRNA mimics 144, 145, 147
 - miRNA modulators 147, 148
 - miRNA-mRNA pairs 144
 - miRNA-mRNA target pair 144
 - miRNA of interest 147
 - miRNA processing enzymes Dicer 147
 - miRNA profiles 142
 - miRNA replacement 145
 - miRNA research 126, 127, 148, 149
 - miRNAs 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149
 - deregulated 140
 - development of 127, 146
 - effect of 132
 - endogenous 145

Subject Index

intronic 130
mediated 131
nuisance 145
pioneer 129
polycistronic 138
precursor 130, 147
regulated 139
seed region of 131, 132
sequestering 133
single 129, 144
suppress 147
underlying 132
miRNA secreting cells 143
miRNA sensors 149
miRNA sequence 130, 145
 targeted mature 145
miRNA sponges 147
miRNA study 142
miRNA target mRNAs 150
miRNA target pair 149
miRNA Targets 144
miRNA therapeutics 147, 148
Mitochondria 167, 168, 177
Mitochondrial dysfunction 162, 163,
 177, 178, 179
Mitochondrial function 163, 168, 177,
 178, 179
Mitochondrial permeability transition
 pore (MPTP) 163, 177, 178
Model of facial inflammatory pain in
 mouse 136
Modifications 145, 164, 165, 168
 chemical 145
 slight 164, 165, 168
Modulate miRNA expression 146
Modulate pain transmission 139
Motor cortex stimulations 26, 27

Pain: Causes, Concerns and Consequences 3;5

MPFC-amygdala pathway 17, 32, 33,
 34, 35, 36
MPTP opening 163, 178, 179
mRNA degradation 131, 132
MT-ACC pathways 34, 35
MT-ACC pathways and pain matrix 35
Music therapy 51, 52
Myocardial infarction (MI) 41, 42, 52
Myocardial ischemia 41, 42, 43, 44, 45,
 47
Myocardium 41, 42

N

Nerve growth factor (NGF) 75
Nerve injury 81, 82, 135, 137, 139
Nerves, sciatic 137, 166, 167, 168
Neural activity 3, 7, 8, 9, 10
Neural correlation hypothesis of CPSP
 17, 35, 36
Neural substrates 20, 22, 23, 24, 27, 32,
 33, 34
Neurodegeneration 177, 178
Neuropathic 138, 142
Neuropathic pain 18, 75, 81, 90, 126,
 128, 133, 134, 135, 136, 137, 138,
 139, 140, 141, 161, 162, 163, 164,
 176, 177, 178, 179
 chemical associated 163
 chronic 75, 128
 diabetic 136
 induced 161, 163, 178, 179
 induced nociceptive 176
 inducing 81, 161, 162
 late phase of 133, 138
 low 135
 maintenance of 134, 139

- management of 162, 163
 - models of 140, 141
 - peripheral 177
 - Neuropathic pain behavior 80
 - Neuropathic pain disorder 163, 179
 - Neuropathic pain induction 139, 140, 141, 164
 - Neuropathic pain states 138, 142
 - Neuropathic pain symptoms 178
 - Neuropathic pain syndrome 162
 - Neuroplasticity 3, 8
 - Nociceptive pain 128
 - Nociceptive pathway 7, 126, 134
 - Nociceptive stimulation 23, 25, 26
 - electrical 23, 25
 - Nociceptors 74, 77, 79, 82, 128, 143
 - Non-cardiac chest pain (NCCP) 40, 41, 50, 53, 54, 55, 56, 58, 59
 - Noradrenaline 89, 91
 - Norepinephrine 79
 - Novel pain modulators 143
 - Noxious stimuli 7, 18, 74, 137
 - NRS pain scores 85
 - Nucleotides 128, 130, 132, 144, 145
 - Numerical pain scale 87
 - Numerical rating scale 94
- O**
- Oesophageal abnormalities 55
 - O-methoxyethyl 145
 - Opioid receptor binding 23
 - Opioid receptors 86, 90, 139, 140, 142
 - Orofacial pain 3, 4, 8, 11
 - chronic 4
 - chronic idiopathic 8
 - unresponsive 11
 - Orofacial pain clinic 13
 - Osteoarthritis 79, 83, 84, 85, 87, 89, 92, 127
 - Oswestry disability index (ODI) 94, 95
 - Oxidase activity 161, 167, 169, 170, 175, 177, 178
 - Oxidase activity and ATP content 167, 169
- P**
- P2X3 receptors *via* phospholipase C (PLC) 90
 - Pain 3, 9, 11, 18, 21, 23, 24, 27, 28, 41, 45, 53, 55, 56, 57, 75, 76, 79, 89, 90, 111, 112, 127, 138, 139, 141, 148
 - acute 24, 112, 127
 - cardiac-origin 53
 - cardiac-related 57
 - cause pleuritic 41
 - chemical 79
 - chronic migraine 23
 - chronic non-cancer 111, 112
 - cystitis-induced chronic 148
 - deafferentation 18
 - exacerbate 45
 - idiopathic 3, 11
 - infectious pericarditis 41
 - inflammatory muscle 139
 - intensified 56
 - isolated musculoskeletal chest wall 55
 - mechanical 27, 28, 75, 76
 - musculoskeletal chest wall 55
 - neurogenic 21
 - operative 90

Subject Index

osteoarthritic 138, 141
paroxysmal 18
pathological 127
pathological chronic 127
physiological 138
refractory post-stroke 21
reuptake inhibitors attenuate 89
severe chronic 9
tumor-associated 138
Pain alongwith parallel 73
Pain Catastrophising Score (PCS) 91,
93, 95
Pain circuitry 33
Pain confrontation strategies 50, 51
Pain disc hernia 94
Painful sensations 44
Pain haplotypes 92
Pain hyperalgesia 93
Pain limb amputation 85
Pain management, effective 10, 12
Pain matrix 5, 22, 23, 24, 25, 26, 33, 34,
35
cortical 24, 33
neural 5
Pain mechanisms 28
Pain mediators 18
Pain pathology 142
Pain pathophysiology 126, 127, 137,
142
Pain processing 94
augmented cortical 94
reducing 94
Pain questionnaire 95
Pain-related complaints 42
Pain scale readings, lower 79
Pain self-management 52
Pain sensation 128, 161, 165, 176

Pain: Causes, Concerns and Consequences 3;7

induced nociceptive 161
mechanical 176
nociceptive 165
Pain sensibility 7
Pain sensitivity 51, 74, 77, 166
spinal nociceptive 166
Pain sensitivity scores 95
Pain signaling 126, 128, 136
nociceptive 128
Pain signaling pathway 133
Pain signaling properties 91
Pain signals 76, 82, 83, 86, 88, 113
induced 82
Pain signal transmission 88
Pain states 82, 93, 133, 141
chronic 93, 133, 141
myofacial 82
Pain stimuli 24, 26, 79
acute 24, 26
mechanical 76
Pain stimuli detection 76
Pain stimuli response 85
Pain therapeutics 143, 147
Pain threshold 5, 6, 8, 11, 14, 28, 43,
80, 82, 85, 93, 94, 166, 169, 171,
172
higher 93
individual's 6
low 94
lower 28, 85
lowered 80
nociceptive 166, 169, 171, 172
Pain tolerance and threshold 85
Pain trajectory 73
Pain transduction 78
Pain transmission 83, 89
Pain treatment 149

- Pain vigilance and awareness questionnaire 94
- Parkinson disease and neuropathic pain 178
- Pathogenesis of CPSP 20
- Pathogenesis-related hypotheses of central post-stroke pain 20
- Pathophysiology of CPSP 34
- Paw withdrawal threshold 172, 173
- Peripheral pain 18, 23, 25
- Peripheral sensitization 18
- Phases of pain 73, 74
- Physical factors 9
- Physical symptoms 59, 60
- Plantar test 27, 28, 165, 171, 172
- Polymorphic study 76
- Polymorphism 75, 76, 79, 83, 84, 87, 89, 90, 94
- Poor prognosis 48
- Positron emission tomography (PET) 21, 25, 26, 84, 93
- Posterior cingulate cortex 17, 22, 23, 25, 26, 33
- Posterior insula 17, 22, 23, 24, 25, 26, 33
- Posterior midbrain 23, 25
- Post-operative pain 85
- Postsurgical pain scale 85
- Precision medicine 3
- Prediction, miRNA target 144
- Prediction of animal miRNA targets 144
- Prefrontal cortex 23, 25, 26, 128, 133, 142
- Prelimbic cortex 28, 29, 31, 32, 33, 34
- Pressure pain sensitivity 87, 89
- Pressure pain thresholds 84, 87
- Prevalence of CPSP 18
- Primary motor cortex 30
- Pri-miRNAs 130, 131
- Protein, m-calpain 177
- Protein kinase 82, 91
- Protein kinase beta type II (PKC β II) 75
- Protein kinase C (PKC) 82, 91
- Pseudoaneurysms 46
- Psychological assessment of patients 52
- Psychological disorders 52, 54, 55, 58
- Psychological distress 40, 49, 56, 58, 59
- Psychological risk factors 49
- Psychological stress 40, 47, 48, 50
- Psychoneuroimmunology 3
- Psychosocial factors 6, 13
- Pulmonary disorders 55
- R**
- Radioactivity ratios 28, 31
- Receptors 10, 74, 79, 80, 81, 82, 86, 88, 89, 90, 91
enhanced pain 91
primary 90, 91
- Reduced glutathione 161, 164, 167, 168, 176, 177
- Regulating pain-processing 127
- Regulation of miRNAs 141
- Relaxation training in cardiac patients 51
- Relaxation training in NCCP patients 60
- Rheumatoid arthritis 55, 83, 84, 89
- Ribose moiety 145
- Right hind paw lifting duration 165
- Right hind paw withdrawal threshold 171, 172

Subject Index

RNA-induced silencing complex (RISC) 130, 131, 145

S

Sciatic nerve axotomy (SNA) 135, 136, 140

Secondary motor cortex 29

Sensory deficits 20

Sensory neurons 18, 76, 79, 80, 134, 147, 148

Sequences, precursor miRNA 146

Serotonin 79, 89, 91, 92

Single miRNA inhibition 147

Social support 45, 51, 52

Sodium channels (SC) 77, 81, 139

Somatosensory cortex 17, 22, 23, 24, 25, 26, 27, 30, 33
primary 23, 25, 26, 27
secondary 23, 25

Somatosensory system 128, 133, 134, 142, 162

Spinal nerve ligation (SNL) 134, 135, 136, 138, 139, 140

Spinothalamocortical 33, 35

Spinothalamocortical pathway 17, 18, 20, 21, 22, 23, 33, 35, 36

Spinothalamocortical system 21, 22

Spinothalamocortical pathway 17

Spontaneous pain 19, 21, 35, 143, 162
elicited rapid 143

Standard deviation (SD) 170, 171, 172, 173, 174, 175, 176

Statistical analysis 170, 171, 172, 173, 174, 175, 176

Statistical parametric mapping (SPM) 27, 28, 29, 30

Pain: Causes, Concerns and Consequences 3;9

Stat trait anxiety inventory (STAI) 93

Stimulation, electrical 23, 25, 55

Stimuli 3, 5, 17, 19, 23, 24, 25, 76, 83, 128

cold 23, 25, 76

nociceptive 17, 19, 24, 128

painful 3, 5, 83

Stroke hemorrhage 19, 33

Stroke patients, thalamic 17

Substance, pain-producing 44

Substance use disorder (SUD) 111, 112, 113, 114, 115, 116, 118, 119, 121

T

Tail immersion tests 161, 165, 166, 174, 175

Tail regions 165, 166, 176

Tail withdrawal threshold 174

Targeted miRNA 146

inhibiting 146

Target genes 129, 130, 131, 136, 138, 144, 149

Target mRNAs 129, 132, 144

Temporo-mandibular disorder (TMD) 3, 8, 82, 95

Thalamic lesions 18, 19, 33

Thalamocortical tract 23, 25

Thalamus 17, 20, 21, 23, 26, 27, 28, 29, 32, 33, 34

lateral posterior 26, 27

right 27

Therapies 23, 48, 50, 51, 59, 117, 143, 148

cognitive-behavioral 48, 50, 51, 59, 117

miRNA-based 148

- miRNA-targeted 143
 - pain reduction 23
 - Thermal hyperalgesia 28, 33, 34, 165, 174
 - induced 172, 174
 - Thermal pain 23, 25, 27, 28, 76, 93
 - Thermal pain sensitization 90
 - Thermal pain stimuli 80
 - Thermal pain tests 93
 - Thermal pain thresholds 95
 - Thiobarbituric acid reactive substances (TBARS) 161, 167, 169, 170, 175, 176, 179
 - Thrombosis 43, 44, 163, 177
 - Tissue homogenate 167, 168
 - Tissue injury 166
 - Total calcium 161, 167, 168, 169, 176, 177, 179
 - Total protein content 167
 - Tragic interpretation 59, 60
 - Transcranial magnetic stimulation (TMS) 119
 - Transient receptor potential (TRP) 74, 78
 - Translating miRNA biology 147
 - Translational repression 131, 132
 - Transmission, synaptic 73, 88
 - Treatment of cyclosporin 171, 172, 173, 174, 175
 - Trigeminal ganglion (TG) 126, 128, 137, 138, 140
 - TRP gene family 75, 77
 - TRPV1 knockouts 75
- U**
- Underlying miRNA action 144
 - Unique miRNA expression signatures 133
 - Upregulate MiRNA 144
- V**
- Ventrolateral thalamus nucleus 29, 30
 - Visual analog score (VAS) 78, 79, 84, 85, 86, 87, 88, 93, 94, 95